CN103298464A - 复方组合物 - Google Patents

复方组合物 Download PDF

Info

Publication number
CN103298464A
CN103298464A CN2011800525659A CN201180052565A CN103298464A CN 103298464 A CN103298464 A CN 103298464A CN 2011800525659 A CN2011800525659 A CN 2011800525659A CN 201180052565 A CN201180052565 A CN 201180052565A CN 103298464 A CN103298464 A CN 103298464A
Authority
CN
China
Prior art keywords
ibuprofen
acetaminophen
combination
composition
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800525659A
Other languages
English (en)
Chinese (zh)
Inventor
哈特莱·坎贝尔·爱金逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFT Pharmaceuticals Ltd
Original Assignee
AFT Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103298464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AFT Pharmaceuticals Ltd filed Critical AFT Pharmaceuticals Ltd
Priority to CN201710623266.5A priority Critical patent/CN107519159A/zh
Publication of CN103298464A publication Critical patent/CN103298464A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2011800525659A 2010-11-04 2011-10-26 复方组合物 Pending CN103298464A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710623266.5A CN107519159A (zh) 2010-11-04 2011-10-26 复方组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
NZ589011 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710623266.5A Division CN107519159A (zh) 2010-11-04 2011-10-26 复方组合物

Publications (1)

Publication Number Publication Date
CN103298464A true CN103298464A (zh) 2013-09-11

Family

ID=46024668

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800525659A Pending CN103298464A (zh) 2010-11-04 2011-10-26 复方组合物
CN201710623266.5A Pending CN107519159A (zh) 2010-11-04 2011-10-26 复方组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710623266.5A Pending CN107519159A (zh) 2010-11-04 2011-10-26 复方组合物

Country Status (28)

Country Link
US (6) US20130225685A1 (https=)
EP (1) EP2635269B1 (https=)
JP (2) JP2013541583A (https=)
KR (1) KR101900520B1 (https=)
CN (2) CN103298464A (https=)
AU (1) AU2011324137B2 (https=)
BR (1) BR112013010829B8 (https=)
CA (1) CA2814057C (https=)
CL (1) CL2013001250A1 (https=)
CO (1) CO6771406A2 (https=)
CY (1) CY1123398T1 (https=)
DK (1) DK2635269T3 (https=)
ES (1) ES2742373T3 (https=)
HR (1) HRP20191489T1 (https=)
HU (1) HUE045442T2 (https=)
LT (1) LT2635269T (https=)
MX (2) MX2013005113A (https=)
MY (1) MY160572A (https=)
NZ (1) NZ609727A (https=)
PH (2) PH12013500689A1 (https=)
PL (1) PL2635269T3 (https=)
PT (1) PT2635269T (https=)
RS (1) RS59258B1 (https=)
RU (2) RU2707089C2 (https=)
SG (1) SG189319A1 (https=)
SI (1) SI2635269T1 (https=)
SM (1) SMT201900481T1 (https=)
WO (1) WO2012060719A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794163A (zh) * 2014-07-18 2017-05-31 光大制药有限公司 包含对乙酰氨基酚和布洛芬的水性制剂
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛
CN113795243A (zh) * 2019-02-27 2021-12-14 Aft制药有限公司 含有对乙酰氨基酚和布洛芬的药物组合物
US11413241B2 (en) 2017-04-20 2022-08-16 Hyloris Developments Sa Method for preparing a composition with a low dissolved oxygen content, comprising acetaminophen, and optionally one or more NSAIDs, and a composition obtained thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
CN114681324B (zh) * 2017-07-10 2024-05-03 盖尔凯普科技有限公司 双释放剂型胶囊及其制备方法、装置和系统
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1758904A (zh) * 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 非甾体抗炎药物的给药方案
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
CN101022789A (zh) * 2004-07-07 2007-08-22 Aft制药有限公司 一种药物组合物
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
DE60114249T2 (de) * 2001-11-02 2006-05-18 Cumberland Pharmaceuticals Inc., Nashville Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
CA2666582C (en) * 2006-10-20 2014-09-09 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations
US20110166234A1 (en) * 2008-10-14 2011-07-07 Atkinson Hartley Campbell Medicinal product and treatment
KR20140014350A (ko) * 2009-03-12 2014-02-06 큠버랜드 파마슈티컬즈 인코포레이티드 정맥 내 투여용 이부프로펜의 투여
SG186388A1 (en) * 2010-07-07 2013-01-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
KR20170066549A (ko) * 2014-10-06 2017-06-14 큠버랜드 파마슈티컬즈 인코포레이티드 통증 치료를 위한 이부프로펜과 아세트아미노펜의 공동 정맥 투여

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1758904A (zh) * 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 非甾体抗炎药物的给药方案
CN101022789A (zh) * 2004-07-07 2007-08-22 Aft制药有限公司 一种药物组合物
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106794163A (zh) * 2014-07-18 2017-05-31 光大制药有限公司 包含对乙酰氨基酚和布洛芬的水性制剂
CN113018258A (zh) * 2014-07-18 2021-06-25 海罗利斯制药股份公司 包含对乙酰氨基酚和布洛芬的水性制剂
US11213498B2 (en) 2014-07-18 2022-01-04 Hyloris Pharmaceuticals S.A. Aqueous formulation comprising paracetamol and ibuprofen
US11219609B2 (en) 2014-07-18 2022-01-11 Hyloris Pharmaceuticals SA Aqueous formulation comprising paracetamol and ibuprofen
US11389416B2 (en) 2014-07-18 2022-07-19 Hyloris Pharmaceuticals SA Aqueous formulation comprising paracetamol and ibuprofen
US12083087B2 (en) 2014-07-18 2024-09-10 Hyloris Pharmaceuticals SA Aqueous formulation comprising paracetamol and ibuprofen
CN106999454A (zh) * 2014-10-06 2017-08-01 坎伯兰医药品股份有限公司 共同施用静脉内布洛芬和对乙酰氨基酚以治疗疼痛
US11413241B2 (en) 2017-04-20 2022-08-16 Hyloris Developments Sa Method for preparing a composition with a low dissolved oxygen content, comprising acetaminophen, and optionally one or more NSAIDs, and a composition obtained thereof
CN113795243A (zh) * 2019-02-27 2021-12-14 Aft制药有限公司 含有对乙酰氨基酚和布洛芬的药物组合物
US11534407B2 (en) 2019-02-27 2022-12-27 Aft Pharmaceuticals Limited Pharmaceutical compostion containing acetominophen and ibuprofen
US11872317B2 (en) 2019-02-27 2024-01-16 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetominophen and ibuprofen
US12194151B2 (en) 2019-02-27 2025-01-14 Aft Pharmaceuticals Limited Pharmaceutical compostion containing acetominophen and ibuprofen

Also Published As

Publication number Publication date
BR112013010829A2 (pt) 2016-08-16
US20190029982A1 (en) 2019-01-31
KR101900520B1 (ko) 2018-09-19
RU2015103107A (ru) 2015-06-20
SI2635269T1 (sl) 2019-10-30
US20250134839A1 (en) 2025-05-01
EP2635269A1 (en) 2013-09-11
CN107519159A (zh) 2017-12-29
US20160235695A1 (en) 2016-08-18
RU2015103107A3 (https=) 2018-08-20
CL2013001250A1 (es) 2013-08-30
BR112013010829B8 (pt) 2022-01-04
RU2707089C2 (ru) 2019-11-22
PT2635269T (pt) 2019-09-04
DK2635269T3 (da) 2019-08-26
CO6771406A2 (es) 2013-10-15
LT2635269T (lt) 2019-09-10
US11896567B2 (en) 2024-02-13
CY1123398T1 (el) 2021-10-29
NZ609727A (en) 2015-07-31
RU2013123646A (ru) 2014-12-10
SMT201900481T1 (it) 2019-11-13
HUE045442T2 (hu) 2019-12-30
MX367209B (es) 2019-07-22
JP2017132791A (ja) 2017-08-03
AU2011324137A1 (en) 2013-05-02
US12220392B2 (en) 2025-02-11
HRP20191489T1 (hr) 2019-11-15
JP2013541583A (ja) 2013-11-14
MY160572A (en) 2017-03-15
PH12013500689A1 (en) 2013-05-27
WO2012060719A1 (en) 2012-05-10
AU2011324137B2 (en) 2015-05-07
MX2013005113A (es) 2013-06-03
RS59258B1 (sr) 2019-10-31
EP2635269B1 (en) 2019-05-22
JP6353577B2 (ja) 2018-07-04
BR112013010829B1 (pt) 2021-12-21
PL2635269T3 (pl) 2019-11-29
US20230000805A1 (en) 2023-01-05
SG189319A1 (en) 2013-05-31
KR20140025314A (ko) 2014-03-04
US11446266B2 (en) 2022-09-20
US20130225685A1 (en) 2013-08-29
ES2742373T3 (es) 2020-02-14
CA2814057C (en) 2022-02-01
US20240207210A1 (en) 2024-06-27
PH12021550804A1 (en) 2022-02-14
CA2814057A1 (en) 2012-05-10
EP2635269A4 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
US12220392B2 (en) Combination composition
CA2867343C (en) Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
RU2592983C2 (ru) Комбинированная терапия, включающая вемурафениб и интерферон, для применения в лечении рака
AU2011274652B2 (en) A combination composition comprising ibuprofen and paracetamol
KR20120138229A (ko) 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物
JP6856813B1 (ja) 亜鉛点滴静注用製剤
JP2020532564A (ja) カルシウム補給用組成物
CN121868318A (zh) 联合治疗乳腺癌骨转移的药物
JP5336527B2 (ja) リドカイン含有ゼリー剤
HUP9902891A2 (hu) Késleltetett kezdetű hányás kezelésére szolgáló metoklopranidtartalmú intranazális spray-készítmény
CN107970248A (zh) 异甘草酸在制备治疗高血压药物中的用途
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130911

RJ01 Rejection of invention patent application after publication